A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

Gynecologic Oncology

Volumn 95, Issue 3, 2004, Pages 624-631

  Berkenblit, Anna ^a   Seiden, Michael V ^b   Matulonis, Ursula A ^c   Penson, Richard T ^b   Krasner, Carolyn N ^b   Roche, Maria ^b   Mezzetti, Lisa ^b   Atkinson, Tina ^c   Cannistra, Stephen A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; PLATINUM;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BODY WEIGHT DISORDER; CANCER RESISTANCE; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LACRIMATION; LIVER DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; ONYCHOLYSIS; OVARY CANCER; PERIPHERAL EDEMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; UTERINE TUBE TUMOR; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAXOIDS;

EID: 9944253001     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.08.028     Document Type: Article

References (37)

1. S.A. Cannistra Cancer of the ovary N. Engl. J. Med. 329 1993 1550 1559
2. R.F. Ozols Treatment of recurrent ovarian cancer: increasing options- "recurrent" results J. Clin. Oncol. 15 1997 2177 2180
3. R.F. Ozols Recurrent ovarian cancer: evidence-based treatment [comment] J. Clin. Oncol. 20 2002 1161 1163
4. S.A. Cannistra Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J. Clin. Oncol. 20 2002 1158 1160
5. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol. Oncol. 36 1990 207 211
6. M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J. Clin. Oncol. 9 1991 389 393
7. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [see comment] J. Clin. Oncol. 15 1997 2183 2193
8. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
9. J.T. Thigpen, J.A. Blessing, H. Ball, S.J. Hummel, and R.J. Barrett Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J. Clin. Oncol. 12 1994 1748 1753
10. L.R. Kelland, and G. Abel Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines Cancer Chemother. Pharmacol. 30 1992 444 450
11. D. Fennelly, C. Aghajanian, F. Shapiro, C. O'Flaherty, M. McKenzie, and C. O'Connor Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer J. Clin. Oncol. 15 1997 187 192
12. N.R. Abu-Rustum, C. Aghajanian, R.R. Barakat, D. Fennelly, F. Shapiro, and D. Spriggs Salvage weekly paclitaxel in recurrent ovarian cancer Semin. Oncol. 24 1997 S15-62 S15-67
13. P.G. Rose, J.A. Blessing, H.G. Ball, J. Hoffman, D. Warshal, and K. DeGeest A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 88 2003 130 135
14. V. Valero, S.E. Jones, D.D. Von Hoff, D.J. Booser, R.G. Mennel, and P.M. Ravdin A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer J. Clin. Oncol. 16 1998 3362 3368
15. C.F. Verschraegen, T. Sittisomwong, A.P. Kudelka, E. Guedes, M. Steger, and T. Nelson-Taylor Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma J. Clin. Oncol. 18 2000 2733 2739
16. P. Garcia, D. Braguer, G. Carles, S. el Khyari, Y. Barra, and C. de Ines Comparative effects of taxol and Taxotere on two different human carcinoma cell lines Cancer Chemother. Pharmacol. 34 1994 335 343
17. J.F. Riou, A. Naudin, and F. Lavelle Effects of Taxotere on murine and human tumor cell lines Biochem. Biophys. Res. Commun. 187 1992 164 170
18. I. Ringel, and S.B. Horwitz Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol J. Natl. Cancer Inst. 83 1991 288 291
19. P. Vasey Preliminary results of the SCOTROC Trial: a Phase III comparison of Paclitaxel-Carboplatin (PC) and Docetaxel-Carboplatin (DC) as first-line chemotherapy for stage Ic-IV Epithelial Ovarian Cancer (EOC) Proc. ASCO 2001
20. P.A. Vasey Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer J. Clin. Oncol. 21 2003 136 144
21. P.A. Vasey Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC) PASCO 2002
22. S.A. Cannistra, R.C. Bast, J.S. Berek, M.A. Bookman, C.P. Crum, and P.D. DePriest Progress in the management of gynecologic cancer: consensus summary statement J. Clin. Oncol. 21 2003 129 132
23. P. Francis, J. Schneider, L. Hann, C. Balmaceda, R. Barakat, and M. Phillips Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer J. Clin. Oncol. 12 1994 2301 2308
24. M.J. Piccart, M. Gore, W. Ten Bokkel Huinink, A. Van Oosterom, J. Verweij, and J. Wanders Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer J. Natl. Cancer Inst. 87 1995 676 681
25. J.J. Kavanagh, A.P. Kudelka, C.G. de Leon, D. Tresukosol, M. Hord, and M.B. Finnegan Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum Clin. Cancer Res. 2 1996 837 842
26. N. Katsumata, R. Tsunematsu, K. Tanaka, Y. Terashima, S. Ogita, and H. Hoshiai A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study Ann. Oncol. 11 2000 1531 1536
27. J.D. Hainsworth, H.A. Burris, J.B. Erland, M. Thomas, F.A. Greco, and H.A. Burris III Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer J. Clin. Oncol. 16 1998 2164 2168
28. H.J. Burstein, J. Manola, J. Younger, L.M. Parker, C.A. Bunnell, and R. Scheib Docetaxel administered on a weekly basis for metastatic breast cancer J. Clin. Oncol. 18 2000 1212 1219
29. G. Gravis, F. Bladou, N. Salem, G. Macquart-Moulin, G. Serment, and J. Camerlo Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma Cancer 98 2003 1627 1634
30. R. Simon Optimal two-stage designs for phase II clinical trials Controlled Clin. Trials 10 1989 1 10
31. G.J.S. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J. Clin. Oncol. 21 2003 187s 193s
32. M. Markman, K. Zanotti, K. Webster, G. Peterson, B. Kulp, and J. Belinson Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum Gynecol. Oncol. 91 2003 573 576
33. M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, and L. Van Le Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J. Clin. Oncol. 20 2002 2365 2369
34. B. Esmaeli, G. Hortobagyi, F. Esteva, V. Valero, M.A. Ahmadi, and D. Booser Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect Ann. Oncol. 13 2002 218 221
35. B. Esmaeli, G.N. Hortobagyi, F.J. Esteva, D. Booser, M.A. Ahmadi, and E. Rivera Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer Ophthalmology 109 2002 1188 1191
36. J. Raley, J.P. Geisler, T.E. Buekers, and J.I. Sorosky Docetaxel extravasation causing significant delayed tissue injury Gynecol. Oncol. 78 2000 259 260
37. A. Berkenblit, N. Tung, Y. Kim, H. Feyler, J. Niloff, and K.V. Berghe Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of mullerian origin Gynecol. Oncol. 89 2003 486 493